Tim Nestler1, Hans Schmelz2, Arndt-Christian Müller3, Christoph Seidel4. 1. Klinik für Urologie, Bundeswehrzentralkrankenhaus Koblenz, Rübenacherstraße 170, 56072, Koblenz, Deutschland. tim.nestler@uk-koeln.de. 2. Klinik für Urologie, Bundeswehrzentralkrankenhaus Koblenz, Rübenacherstraße 170, 56072, Koblenz, Deutschland. 3. Klinik für Radioonkologie und Strahlentherapie, RKH Kliniken Ludwigsburg-Bietigheim, Ludwigsburg, Deutschland. 4. Klinik Onkologie, Hämatologie und Stammzelltransplantation mit Abteilung für Pneumologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Abstract
BACKGROUND: Metastatic testicular germ cell tumors patients require histology- and stage-appropriate therapy to achieve optimal therapeutic outcomes. OBJECTIVES: This work focuses on the interdisciplinary presentation of current recommendations for the treatment of metastatic germ cell tumor patients. MATERIALS AND METHODS: The interdisciplinary recommendations were formulated based on the German S3 guideline and supplemented by recent literature. RESULTS: Using a stage-specific and guideline-based treatment approach, interdisciplinary cooperation between urology, oncology, and radiotherapy is mandatory to successfully achieve a high rate of cure and, in the case of complex advanced tumors, also the most effective therapy possible. The question of optimal treatment approaches for seminoma in cSII A/B remains particularly challenging. CONCLUSION: Since treatment of advanced or multiple relapsed germ cell tumor patients remains complex, patients should be referred for an online second opinion ( https://urologie.ekonsil.org ).
BACKGROUND: Metastatic testicular germ cell tumors patients require histology- and stage-appropriate therapy to achieve optimal therapeutic outcomes. OBJECTIVES: This work focuses on the interdisciplinary presentation of current recommendations for the treatment of metastatic germ cell tumor patients. MATERIALS AND METHODS: The interdisciplinary recommendations were formulated based on the German S3 guideline and supplemented by recent literature. RESULTS: Using a stage-specific and guideline-based treatment approach, interdisciplinary cooperation between urology, oncology, and radiotherapy is mandatory to successfully achieve a high rate of cure and, in the case of complex advanced tumors, also the most effective therapy possible. The question of optimal treatment approaches for seminoma in cSII A/B remains particularly challenging. CONCLUSION: Since treatment of advanced or multiple relapsed germ cell tumor patients remains complex, patients should be referred for an online second opinion ( https://urologie.ekonsil.org ).
Authors: K Fizazi; S Tjulandin; R Salvioni; J R Germà-Lluch; J Bouzy; D Ragan; C Bokemeyer; A Gerl; A Fléchon; J S de Bono; S Stenning; A Horwich; J Pont; P Albers; U De Giorgi; M Bower; A Bulanov; G Pizzocaro; J Aparicio; C R Nichols; C Théodore; J T Hartmann; H J Schmoll; S B Kaye; S Culine; J P Droz; C Mahé Journal: J Clin Oncol Date: 2001-05-15 Impact factor: 44.544
Authors: K Clint Cary; Jose A Pedrosa; Hristos Z Kaimakliotis; Timothy A Masterson; Lawrence H Einhorn; Richard S Foster Journal: J Urol Date: 2014-09-22 Impact factor: 7.450
Authors: G Daugaard; I Skoneczna; N Aass; R De Wit; M De Santis; H Dumez; S Marreaud; L Collette; J R G Lluch; C Bokemeyer; H J Schmoll Journal: Ann Oncol Date: 2010-11-08 Impact factor: 32.976
Authors: Yaron Ehrlich; Mary J Brames; Stephen D W Beck; Richard S Foster; Lawrence H Einhorn Journal: J Clin Oncol Date: 2009-12-21 Impact factor: 44.544
Authors: R de Wit; G Stoter; S B Kaye; D T Sleijfer; W G Jones; W W ten Bokkel Huinink; L A Rea; L Collette; R Sylvester Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: M Bachner; Y Loriot; M Gross-Goupil; P A Zucali; A Horwich; J-R Germa-Lluch; C Kollmannsberger; F Stoiber; A Fléchon; K Oechsle; S Gillessen; J Oldenburg; G Cohn-Cedermark; G Daugaard; F Morelli; A Sella; S Harland; M Kerst; J Gampe; C Dittrich; K Fizazi; M De Santis Journal: Ann Oncol Date: 2011-04-02 Impact factor: 32.976
Authors: Brett S Carver; Angel M Serio; Dean Bajorin; Robert J Motzer; Jason Stasi; George J Bosl; Andrew J Vickers; Joel Sheinfeld Journal: J Clin Oncol Date: 2007-11-12 Impact factor: 44.544
Authors: P Giannatempo; T Greco; L Mariani; N Nicolai; S Tana; E Farè; D Raggi; L Piva; M Catanzaro; D Biasoni; T Torelli; S Stagni; B Avuzzi; M Maffezzini; G Landoni; F De Braud; A M Gianni; G Sonpavde; R Salvioni; A Necchi Journal: Ann Oncol Date: 2014-09-11 Impact factor: 32.976
Authors: C Bokemeyer; C Kollmannsberger; S Stenning; J T Hartmann; A Horwich; C Clemm; A Gerl; C Meisner; C-P Rückerl; H-J Schmoll; L Kanz; T Oliver Journal: Br J Cancer Date: 2004-08-16 Impact factor: 7.640